Skip to main content

Cencora, Inc.

corporate_fare Company Profile

Cencora, Inc.

COR·NYSE·Trade & Services·CIK 0001140859

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company that helps healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The company provides innovative programs and services to increase the effectiveness and efficiency of the pharmaceutical supply chain for both human and animal health. Cencora distributes a comprehensive range of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services. Its customers include acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, and veterinarians in the United States and select global markets. Additionally, Cencora offers healthcare providers and pharmaceutical manufacturers various related services, such as data analytics, outcomes research, reimbursement and pharmaceutical consulting services (including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance), niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.

Cencora, Inc. (NYSE:COR) is a publicly traded company in the Trade & Services sector. Wiseek monitors COR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Cencora Appoints Eva Boratto as Executive VP and CFO
  • Cencora Appoints Eva Boratto as New CFO, Reaffirms FY26 EPS Guidance
  • Cencora Unveils New $2 Billion Share Buyback, Boosts FY26 EPS Outlook
  • Cencora Boosts FY26 Adjusted EPS Outlook to $17.70-$17.90
  • Cencora Reports Strong Q2 Earnings, Positive Opioid Litigation Update, and Increased Debt for OneOncology Acquisition

Financial Snapshot

Fiscal year ended September 30, 2025
Revenue
$321.33B
Net Income
$1.55B
Diluted EPS
$7.96
Op. Cash Flow
$3.88B
Free Cash Flow
$3.21B
Gross Profit
$11.48B
Operating Income
$2.63B
Cash & Equivalents
$4.36B
Total Debt
$7.66B
Debt / Equity
5.08×
Net Margin
0.5%
Shares Outstanding
193.94M sh
Source: 10-K · filed 2025-11-25 · accession 0001140859-25-000131
Browse all tickers starting with C →
$281.67
52-week range · as of 2026-05-29 $244.82 – $377.54
Market cap
$54.8B
Volume
1.1M (0.5× avg)
3-mo avg 2M
Live data · 2026-06-14 05:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed COR - Latest Insights

COR
May 29, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $269.36
Real-time Price: $281.67 info
Change: +$12.31 (+5%) info
Market Cap: $54.802B info
COR
May 27, 2026, 8:01 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $271.24
Real-time Price: $281.67 info
Change: +$10.43 (+4%) info
Market Cap: $54.802B info
COR
May 21, 2026, 5:11 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $264.25
Real-time Price: $281.67 info
Change: +$17.42 (+7%) info
Market Cap: $54.802B info
COR
May 21, 2026, 4:32 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $267.77
Real-time Price: $281.67 info
Change: +$13.90 (+5%) info
Market Cap: $54.802B info
COR
May 06, 2026, 2:41 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $252.82
Real-time Price: $281.67 info
Change: +$28.85 (+11%) info
Market Cap: $54.802B info
COR
May 06, 2026, 7:39 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $288.00
Real-time Price: $281.67 info
Change: -$6.33 (-2%) info
Market Cap: $54.802B info
COR
May 06, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $309.00
Real-time Price: $281.67 info
Change: -$27.33 (-9%) info
Market Cap: $54.802B info
COR
Mar 23, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $326.76
Real-time Price: $281.67 info
Change: -$45.09 (-14%) info
Market Cap: $54.802B info
COR
Mar 23, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $330.50
Real-time Price: $281.67 info
Change: -$48.83 (-15%) info
Market Cap: $54.802B info
COR
Mar 17, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $338.66
Real-time Price: $281.67 info
Change: -$56.99 (-17%) info
Market Cap: $54.802B info
COR
Feb 18, 2026, 7:34 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $358.83
Real-time Price: $281.67 info
Change: -$77.16 (-22%) info
Market Cap: $54.802B info
COR
Feb 10, 2026, 5:26 PM EST
Filing Type: FWP
Importance Score:
8
Price at Filing: $360.00
Real-time Price: $281.67 info
Change: -$78.33 (-22%) info
Market Cap: $54.802B info
COR
Feb 04, 2026, 2:43 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $329.33
Real-time Price: $281.67 info
Change: -$47.66 (-14%) info
Market Cap: $54.802B info
COR
Feb 04, 2026, 6:31 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $360.01
Real-time Price: $281.67 info
Change: -$78.34 (-22%) info
Market Cap: $54.802B info
COR
Jan 22, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $354.00
Real-time Price: $281.67 info
Change: -$72.33 (-20%) info
Market Cap: $54.802B info
COR
Jan 16, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $356.36
Real-time Price: $281.67 info
Change: -$74.69 (-21%) info
Market Cap: $54.802B info